Journal of the American Society of Hypertension
Volume 3, Issue 3 , Pages 201-209 , May 2009

Cystatin C is associated with the metabolic syndrome and other cardiovascular risk factors in a hypertensive population

  • Luis Vigil, MD

      Affiliations

    • Hypertension Unit, Department of Internal Medicine
    • Corresponding Author InformationCorresponding author: Luis Vigil, MD, Paseo de los Olmos 12 B, Madrid 28005, Spain. Tel: 34 914737448; fax: 34 914737448.
    • ,
  • Manuel Lopez, MD

      Affiliations

    • Hypertension Unit, Department of Internal Medicine
    • ,
  • Emilia Condés, MD

      Affiliations

    • Hypertension Unit, Department of Internal Medicine
    • ,
  • Manuel Varela, MD

      Affiliations

    • Hypertension Unit, Department of Internal Medicine
    • ,
  • Dulce Lorence, MD

      Affiliations

    • Department of Biochemistry, Hospital Universitario de Móstoles, Móstoles, Madrid
    • ,
  • Rafael Garcia-Carretero, MD

      Affiliations

    • Hypertension Unit, Department of Internal Medicine
    • ,
  • Julian Ruiz, MD

      Affiliations

    • Hypertension Unit, Department of Internal Medicine

Received 30 October 2008 ,Accepted 5 January 2009.

References 

  1. Filler G, Bökenkamp A, Hofmann W, Le Bricon T, Martinez-Brú C, Grubb A. Cystatin C as a marker of GFR—history, indications and future research. Clin Biochem. 2005;38:1–8
  2. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis. 2002;40:221–226
  3. Fliser D, Ritz E. Serum cystatin C concentration as a marker of renal dysfunction in the elderly. Am J Kidney Dis. 2001;37:79–83
  4. Coll E, Botey A, Alvarez L, Poch E, Quintó L, Saurina A, et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis. 2000;36:29–34
  5. Mangge H, Liebmann P, Tanil H, Hermann J, Wagner C, Gallistl S, et al. Cystatin C, an early indicator for incipient renal disease in rheumatoid arthritis. Clin Chim Acta. 2000;300:195–202
  6. Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger Sl, Newman AB, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med. 2005;352:2049–2060
  7. Shlipak MG, Wassel Fyr CL, Chertow GM, Harris TB, Kritchevsky SB, Tylavsky FA, et al. Cystatin C and mortality risk in the elderly: the health, aging, and body composition study. J Am Soc Nephrol. 2006;17:254–261
  8. Luc G, Bard JM, Lesueur C, Arveiler D, Evans A, Amouyel P, et al. PRIME Study Group Plasma cystatin C and development of coronary heart disease: the PRIME Study. Atherosclerosis. 2006;185:375–380
  9. Jernberg T, Lindahl B, James S, Larsson A, Hansson LO, Wallentin L. Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation. 2004;110:2342–2348
  10. Koenig W, Twardella D, Brenner H, Rothenbacher D. Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. Clin Chem. 2005;51:321–327
  11. Ix JH, Shlipak MG, Chertow GM, Ali S, Schiller NB, Whooley MA. Cystatin C, left ventricular hypertrophy, and diastolic dysfunction: data from the Heart and Soul Study. J Card Fail. 2006;12:601–607
  12. Ix JH, Shlipak MG, Chertow GM, Whooley MA. Association of Cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study. Circulation. 2007;115:173–179
  13. Zethelius B, Berglund L, Sundström J, Ingelsson E, Basu S, Larsson A, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med. 2008;358:2107–2116
  14. Knight EL, Verhave JC, Spiegelman D, Hillege HL, de Zeeuw D, Curhan GC, et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int. 2004;65:1416–1421
  15. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735–2752
  16. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709–2716
  17. Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med. 2004;140:167–174
  18. Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol. 2005;16:2134–2140
  19. Zhang L, Zuo L, Wang F, Wang M, Wang S, Liu LS, et al. Metabolic syndrome and chronic kidney disease in a Chinese population aged 40 years and older. Mayo Clin Proc. 2007;82:822–827
  20. Ninomiya T, Kiyohara Y, Kubo M, Yonemoto K, Tanizaki Y, Doi Y, et al. Metabolic syndrome and CKD in a general Japanese population: the Hisayama Study. Am J Kidney Dis. 2006;48:383–391
  21. Tozawa M, Iseki C, Tokashiki K, Chinen S, Kohagura K, Kinjo K, et al. Metabolic syndrome and risk of developing chronic kidney disease in Japanese adults. Hypertens Res. 2007;30:937–943
  22. Kitiyakara C, Yamwong S, Cheepudomwit S, Domrongkitchaiporn S, Unkurapinun N, Pakpeankitvatana V, et al. The metabolic syndrome and chronic kidney disease in a Southeast Asian cohort. Kidney Int. 2007;71:693–700
  23. Lee JE, Choi SY, Huh W, Kim YG, Kim DJ, Oh HY. Metabolic syndrome, C-reactive protein, and chronic kidney disease in nondiabetic, nonhypertensive adults. Am J Hypertens. 2007;20:1189–1194
  24. Lucove J, Vupputuri S, Heiss G, North K, Russell M. Metabolic syndrome and the development of CKD in American Indians: the Strong Heart Study. Am J Kidney Dis. 2008;51:21–28
  25. Rashidi A, Ghanbarian A, Azizi F. Are patients who have metabolic syndrome without diabetes at risk for developing chronic kidney disease? Evidence based on data from a large cohort screening population. Clin J Am Soc Nephrol. 2007;2:976–983
  26. Chen J, Gu D, Chen CS, Wu X, Hamm LL, Muntner P, et al. Association between the metabolic syndrome and chronic kidney disease in Chinese adults. Nephrol Dial Transplant. 2007;22:1100–1106
  27. Locatelli F, Pozzoni P, Del Vecchio L. Renal manifestations in the metabolic syndrome. J Am Soc Nephrol. 2006;17:S81–S85
  28. Retnakaran R, Connelly PW, Harris SB, Zinman B, Hanley AJ. Cystatin C is associated with cardiovascular risk factors and metabolic syndrome in Aboriginal youth. Pediatr Nephrol. 2007;22:1007–1013
  29. Demircan N, Gurel A, Armutcu F, Unalacak M, Aktunc E, Atmaca H. The evaluation of serum cystatin C, malondialdehyde, and total antioxidant status in patients with metabolic syndrome. Med Sci Monit. 2008;14:97–101
  30. Servais A, Giral P, Bernard M, Bruckert E, Deray G, Isnard Bagnis C. Is serum cystatin C a reliable marker for metabolic syndrome?. Am J Med. 2008;121:426–432
  31. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  32. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461–470
  33. Erlandsen EJ, Randers E, Kristensen JH. Evaluation of the Dade-Behring N Latex Cystatin C assay on the Dade-Behring Nephelometer II System. Scand J Clin Lab Invest. 1999;59:1–8
  34. Peralta CA, Whooley MA, Ix JH, Shlipak MG. Kidney function and systolic blood pressure new insights from cystatin C: data from the Heart and Soul Study. Am J Hypertens. 2006;19:939–946
  35. Haffner SM. Risk constellations in patients with the metabolic syndrome: epidemiology, diagnosis, and treatment patterns. Am J Med. 2006;19:S3–S9
  36. Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683–689
  37. Shlipak MG, Praught ML, Sarnak MJ. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med. 2006;145:237–246
  38. Herget-Rosenthal S, Trabold S, Pietruck F, Holtmann M, Philipp T, Kribben A. Cystatin C: efficacy as screening test for reduced glomerular filtration rate. Am J Nephrol. 2000;20:97–102
  39. Pucci L, Triscornia S, Lucchesi D, Fotino C, Pellegrini G, Pardini E, et al. Cystatin C and estimates of renal function: searching for a better measure of kidney function in diabetic patients. Clin Chem. 2007;53:480–488
  40. Facchini F, Chen YD, Hollenbeck CB, Reaven GM. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA. 1991;266:3008–3011
  41. Schück O, Teplan V, Stollova M, Skibova J. Estimation of glomerular filtration rate in obese patients with chronic renal impairment based on serum cystatin C levels. Clin Nephrol. 2004;62:92–96
  42. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365:1415–1428
  43. Rodilla E, Costa JA, Pérez Lahiguera F, González C, Miralles A, Pascual JM. Cystatin C and other cardiovascular markers in hypertension. Med Clin (Barc). 2008;130:1–5
  44. Jotoku M, Okura T, Enomoto D, Irita J, Miyoshi Y, Kurata M, et al. Association between serum cystatin C and inflammatory cytokines in patients with essential hypertension [abstract]. J Hypertens. 2008;26:S4
  45. Palaniappan L, Carnethon M, Fortmann SP. Association between microalbuminuria and the metabolic syndrome: NHANES III. Am J Hypertens. 2003;16:952–958
  46. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al. HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286:421–426
  47. Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE Study. Ann Intern Med. 2003;139:901–906
  48. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, et al. Prevention of Renal, Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and no cardiovascular mortality in general population. Circulation. 2002;106:1777–1782

 Conflict of interest: none.

PII: S1933-1711(09)00002-3

doi: 10.1016/j.jash.2009.01.002

Journal of the American Society of Hypertension
Volume 3, Issue 3 , Pages 201-209 , May 2009

Article Tools

* Image Usage & Resolution